Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  20.00 3.88% 535.00 520.00 550.00 535.00 530.00 530.00 62,820 13:42:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 318

Renalytix Ai Share Discussion Threads

Showing 51 to 75 of 750 messages
Chat Pages: Latest  6  5  4  3  2  1
DateSubjectAuthorDiscuss
04/6/2019
09:01
FDH...Unlike other investment platforms, Barclays Smart Investor decided to not differentiate between a US citizen and a UK citizen. Thus, this situation prevents Barclays UK clients (UK citizens) from purchasing certain shares. This is to comply with Regulation S which is a restriction under the US Securities Act preventing US investors from purchasing shares. So Barclays are saying that in order to comply with Regulation S, their decision was to restrict buy trading for 'all' of their clients. In this case preventing purchasing of shares in Renalytix!
wan
04/6/2019
08:37
Hi wan, could you please explain "Shame on Barclays for not allowing UK investors to increase exposure/take part" "increase exposure/take part" in what? Only bought into RENX a few weeks back. Thanks in anticipation. FDH
fardistanthills
04/6/2019
07:50
Another key milestone achieved for scaled commercial test production as we approach commercial launch of KidneyIntelX(TM), which is expected in the of 2019. It is refreshing to see a company routinely delivering upon what they stated in terms of both milestones and timescales.......long may that continue! Shame on Barclays for not allowing UK investors to increase exposure/take part!!!
wan
28/5/2019
07:40
Another welcome update as we advance towards commercial operation.
wan
24/5/2019
07:36
Renalytix tweeted to highlight that U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes. The FDA grants Priority Review to medicines that may offer significant improvements in the treatment, diagnosis or prevention of a serious condition. This designation shortens the review period to six months compared to 10 months for Standard Review. If approved, INVOKANA® will be the first and only therapy in nearly 20 years indicated to reduce the risk of kidney failure when added to current standard of care Application was submitted in March 2019 based on landmark phase 3 CREDENCE renal outcomes study published in the New England Journal of Medicine Raritan, NJ (May 22, 2019) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental New Drug Application (sNDA) for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), the doubling of serum creatinine, and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD). If approved for this new indication, INVOKANA® will be the first and only diabetes medicine to treat CKD in patients with T2D. Full release - hTTps://tinyurl.com/FDA-Priority-Review
wan
21/5/2019
07:34
Today's news regarding the expansion of FractalDx core investigator group is perhaps put into better perspective by the fact that the investigator group has doubled in size! With clinical validation for the first diagnostic product from the portfolio beginning in the second half of 2019, there is certainly a focusing of expert minds.
wan
20/5/2019
08:10
Persistent Systems Published on 14 May 2019 Developing new solutions to treat kidney disease proactively, it’s essential for RenalytixAI to bring their products to market faster. As CTO and co-founder, Fergus Fleming says, “Working with a company that has the scale and breadth of Persistent, we can bring two key aspects together; data science and AI capabilities, coupled with the development of complex and integrated software solutions which come together with our products.” Watch video to learn more. hTTps://www.youtube.com/watch?v=a550iD5qWqw&feature=youtu.be
wan
16/5/2019
12:15
Physiomics are on a mission today in terms of tweets and their first ever blog post explaining their Virtual Tumour model (coincides (coincidentally?) with major news carried on BBC etc about their partners/collaborators ICR (Institute of Cancer Research) launching £75m new cancer breakthrough treatments centre hTtps://www.bbc.co.uk/news/health-48290757 ). Tweet :- hTtps://twitter.com/Physiomics/status/1128971257230364672 Blog post :- hTtps://www.physiomics.co.uk/category/blog/ Reminder : PYC Mkt Cap £3m (Rev £0.5m) RENX Mkt Cap £100m (Rev £0m) SENS Mkt Cap £200m (Rev £0m)
the stigologist
14/5/2019
08:22
New Study Finds Chronic Kidney Disease Remains Largely Undiagnosed in Nearly Half of Patients with Type 2 Diabetes and Chronic Kidney Disease Worldwide, 160 million people with type 2 diabetes (T2D) are at risk for developing chronic kidney disease (CKD)1 Study underscores the need for increased education focused on diagnosing and treating patients with T2D and CKD May 10, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new, retrospective, observational study showing 49 percent of patients with type 2 diabetes (T2D) and lab-confirmed chronic kidney disease (CKD) did not have a CKD diagnosis from their doctor in a claims database. The 123,000-patient study, titled Prevalence and Factors Associated with Undiagnosed Chronic Kidney Disease in Diabetes Mellitus, was presented this week at the National Kidney Foundation (NKF) 2019 Spring Clinical Meetings in Boston, Mass. Full release - hTTps://tinyurl.com/Undiagnosed-CKD
wan
10/5/2019
15:33
post 41 thanks wan
9degrees
10/5/2019
07:40
Renalytix tweeted the following (15 hours ago) - Dr. Coca gave a talk on "Optimizing Drug Development via Progressive Disease Enrichment of Clinical Trial Populations" at CKD-3 summit on May 7th. After his talk, Dr. Aliza Thompson of the FDA commented and agreed that continuous risk scores should be employed for enrichment. hTTps://twitter.com/renalytixai?lang=en It's also worth browsing the agenda's - May 6-8 Boston, MA, USA The 2nd Chronic Kidney Disease Drug Development (CKD3) focuses on demonstrating greater therapeutics efficacy than the current standard of care. Now including FDA and analysis of the CREDENCE trial by Janssen R&D * Chronic Kidney Disease Drug Development (CKD3) focuses exclusively on overcoming challenges limiting the development of more efficacious and disease-modifying drugs against diabetic nephropathy, genetic and glomerular kidney disease. Incorporating insights from 32 world class experts including regulatory updates from the FDA, and analysis of the results from CREDENCE by Janssen R&D; this uniquely specific forum assesses key clinical and translational hurdles and the hottest emerging research necessary to achieve the potential of next-generation CKD drugs. hTTps://ckd3-summit.com/day-1/ hTTps://ckd3-summit.com/day-2/
wan
10/5/2019
05:18
9Degrees...Apparently' it's because when the shares were listed they were unavailable to US investors (Regulation F I think). This should not ordinarily be a problem (if you are not a US citizen), however, Barclays Smart Investor platform cannot distinguish a buyers nationality and thus the platform (arguably a Barclays decision!) does not allow purchases in Renalytix (which is perverse that we ended up with the stock and can sell via Barclays). This is very poor indeed, because they should be able to tell an individuals nationality given the information required and held, and it's a 'very' frustrating situation to say the least! I have escalated the situation to an official complaint!
wan
07/5/2019
16:27
on Barclays smartinvestor can only sell but not buy. Why not Barclays ???
9degrees
07/5/2019
15:41
UK leads the field in Healthcare/Biotech/Pharma AI/Machine Learning Unlisted entities Google Deepmind $500m+ Benevolent AI $2000m+ ExScientia $1000m+ Listed entities #RENX £90m #SENS £230m #PYC £2m Physiomics is undervalued by multiples. Only a matter of time before a moonshoot News today re ExScientia :- hTtps://www.thecourier.co.uk/fp/business/business-news/886017/dundee-firm-could-be-worth-more-than-1-billion-if-listed-on-stock-exchange/ https://www.telegraph.co.uk/technology/2019/05/05/dundee-professors-could-line-500m-future-exscientia-debut/
the stigologist
07/5/2019
15:21
cant buy nt trade only possible 2.20 finnish
msufi77
07/5/2019
11:51
Looks a good stock, I am in (STX) from early days, awaiting FDA decision 27 July, so happy to start investing here, could do with a little pull back though!
ny boy
07/5/2019
07:37
Today's news provides for further encouraging development, and underscores previous news flow regarding the ability to develop companion diagnostics, which in turn implies to me (at least), that the 'overall' offering from Renalytix is likely to be of increasing interest to drug developers.....cue my previous post 31!
wan
02/5/2019
07:34
The excellent rate of progress continues, as another key operational milestone is successfully delivered!
wan
26/4/2019
07:06
The Company is pleased to confirm that relevant EKF shareholders on the register as at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held. Entitlements will be rounded down to the nearest whole number of RENX Shares and fractional entitlements will be aggregated and sold in the open market with the net proceeds donated to charity, in line with the Company's articles.
pugugly
26/4/2019
06:22
Please can someone remind me of the basis for the issue of free shares in RENX as a proportion of ones holding in EKF at the time of the announcement. My allowance has suddenly arrived in my sipp without any detail to allow me to check it's accuracy. Many thanks, CD
cambridgedon
21/4/2019
20:42
Cheers Wan
wilsonst1
21/4/2019
07:35
Given the impending end of the lock-up period, this morning I caught up with some further Renalytix research. In particular the recent investor briefing/presentation and the recent CREDENCE trial results (funded by the pharmaceutical company Janssen who manufactures the Invokana) and the subsequent news flow. Some thought provoking CREDENCE news flow - Janssen Pharmaceuticals Diabetes Drug May Also Prevent, Slow Kidney Disease 15 April 2019 hTTps://www.techtimes.com/articles/241524/20190415/janssen-pharmaceuticals-diabetes-drug-may-also-prevent-slow-kidney-disease.htm 17 APRIL, 2019 A landmark clinical trial has provided “renewed optimism” for patients with type 2 diabetes and kidney disease, after researchers found a drug reduced the risk of renal failure by almost a third. hTTps://www.nursingtimes.net/news/diabetes/drug-reduces-risk-of-kidney-failure-for-type-2-diabetes-patients/7028638.article 15th April 2019 Johnson & Johnson's diabetes drug Invokana has shown it can slow down kidney disease or even prevent it all together. The results from the phase 3 CREDENCE study are an important boost for Invokana, which is trailing behind other competitors in the SGLT2 inhibitor class in terms of market share. The trial puts Invokana one step ahead of rivals, such as AstraZeneca, the renal outcomes study for its SGLT2 drug Farxiga due in November 2020. Meanwhile Sanofi and Lexicon's Zynquista and Eli Lilly and Boehringer Ingeheim's market leader Jardiance are also both in renal outcomes trials, with their respective results expected by 2022. It seems likely that the other drugs in the class will also prove their value in kidney disease - just as protection against heart disease has been proven in cardiovascular outcomes trials across the class. Analysts expect Jardiance to maintain its lead in the field over this period, with Evaluate Pharma forecasting it will hit revenues of $3.51bn by 2024. Full story - hTTps://www.pmlive.com/pharma_news/j_and_js_invokana_shows_potential_in_kidney_disease_prevention_1284516 As the above indicates, there are more trial outcomes to follow and a wall of money flowing into the potential treatment of kidney disease. However, without effective diagnostics, dare I suggest 'companion' diagnostics and thus effective management of kidney disease, the ultimate goal of 'effective' treatment will still be missed......cue RenalytixAI proposals! I found the Investor briefing informative overall, and given the CREDENCE trial results and news flow, slides 24 and 25 particularly stood out. Slide 24 - Advanced Diagnostics + Novel Drug Development = Personalized Medicine We’ve done it in cancer Now its time for the kidney and slide 25 - The age of personalized drug therapy for kidney is here (SGLT2 Inhibitors) hTTps://renalytixai.com/wp-content/uploads/2019/03/RENX_Investor_presentation_25-03-19.pdf
wan
01/4/2019
09:52
tks wan for yr valuable input . v quiet thread so far but am sure it will warm up after 22 april when we can trade those transferred shares
9degrees
01/4/2019
07:53
Another very encouraging announcement today, details of which provides a notable stride towards validation of KidneyIntelX and certainly focuses attention on the previously initiates Clinical Validation Study (initiated in January), which if successful will provide for a significant value inflection point.
wan
25/3/2019
07:40
The inaugural interim results makes for interesting reading and details the excellent progress to date. They also detail the near/medium term operational milestones, which they appear confident about delivering upon and is very encouraging, especially as they envisage that they represent value inflection points. Publication, in the coming days, of the results from a confirmation study will no doubt also make for encouraging reading.
wan
Chat Pages: Latest  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200919 03:50:16